Filing Details

Accession Number:
0000820081-14-000030
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-09-04 16:07:29
Reporting Period:
2014-09-02
Filing Date:
2014-09-04
Accepted Time:
2014-09-04 16:07:29
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
820081 Cambrex Corp CBM Pharmaceutical Preparations (2834) 222476135
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1192621 M Steven Klosk One Meadowlands Plaza
East Rutherford NJ 07073
President & Ceo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-09-02 60,000 $5.61 205,870 No 4 M Direct
Common Stock Disposition 2014-09-02 60,000 $22.01 145,870 No 4 S Direct
Common Stock Acquisiton 2014-09-03 66,257 $5.61 212,127 No 4 M Direct
Common Stock Disposition 2014-09-03 66,257 $22.02 145,870 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2014-09-02 60,000 $0.00 60,000 $5.61
Common Stock Stock Option (Right to Buy) Disposition 2014-09-03 66,257 $0.00 66,257 $5.61
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
66,257 2015-05-14 No 4 M Direct
0 2015-05-14 No 4 M Direct
Footnotes
  1. The option, representing a right to purchase a total of 150,000 shares, became exercisable in four equal annual installments beginning on May 14, 2009, which was the first anniversary of the date on which the option was granted.
  2. The price reported in Column 4 in Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.0 to $22.19 inclusive. The reporting person undertakes to provide to Cambrex Corporation, any security holder of Cambrex Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote (2) to this Form 4.
  3. The price reported in Column 4 in Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.0 to $22.135 inclusive. The reporting person undertakes to provide to Cambrex Corporation, any security holder of Cambrex Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote (3) to this Form 4.